{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:16:30Z","timestamp":1791335790470,"version":"4.3.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A highly accurate, rapid, and low-cost COVID-19 test is essential for guiding isolation measures. To date, the most widely used tests are either nucleic acid amplification tests or antigen tests. The objective of this study is to further assess the diagnostic performance of the Binax-CoV2 rapid antigen test in comparison to the current gold standard reverse transcription quantitative polymerase chain reaction (RT-qPCR), with additional analysis of symptomatology and cycle threshold utility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a prospective cohort study performed between November and December 2020. Individuals who presented to COVID-19 testing events and received both RT-qPCR and\u00a0a rapid\u00a0antigent test were included. Testing occurred at the emergency department of an urban hospital and at a community mobile unit. No fees or appointments were required. Individuals self-reported the\u00a0presence or absence of symptoms and history of positive COVID-19 test within the previous two\u00a0weeks. Trained staff collected two subsequent nasopharyngeal swabs of both nares. One set\u00a0of swabs underwent RT-qPCR and the other underwent Binax-CoV2 assay per manufacturer guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 390 patients were included, of which\u00a0302 were from the community site. Of these 302, 42 (14%) were RT-qPCR positive. Of the 42 RT-qPCR positive, 30 (71.4%) were also positive by Binax-CoV2. The Binax-CoV2 test had a sensitivity of 71.4% (95% CI: 55%\u201384%) and a\u00a0specificity of 99.6% (95% CI: 98%\u2013100%) in this population. Performance of the Binax-CoV2 test performed better in individuals with\u00a0higher viral load. For symptomatic patients with cycle threshold\u2009&lt;\u200920, sensitivity reached 100%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The Binax-CoV2 assay\u2019s specificity and sensitivity in individuals with high viral load makes it a suitable first-line test for detecting COVID-19. However, given the assay\u2019s measured sensitivity, a negative result on the Binax-CoV2 assay may warrant additional testing with more sensitive tests, such as the RT-qPCR. This is particularly the case with high clinical suspicion for an active SARS-CoV-2 infection even after a negative Binax-CoV2 result.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08171-6","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:03:37Z","timestamp":1681819417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Should rapid antigen tests be first-line for COVID-19 testing? Results of a prospective urban cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Mohamad Rani","family":"Hassoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan T.","family":"Kudlapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Green-Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlesha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"5","key":"8171_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time [published correction appears in Lancet Infect Dis. 2020 Sep;20(9):e215]. Lancet Infect Dis. 2020;20(5):533\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"8171_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jama.2021.11042","volume":"326","author":"A Kofman","year":"2021","unstructured":"Kofman A, Kantor R, Adashi EY. Potential COVID-19 endgame scenarios: eradication, elimination, cohabitation, or conflagration? JAMA. 2021;326(4):303\u20134.","journal-title":"JAMA"},{"key":"8171_CR3","unstructured":"Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing for SARS-CoV-2. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/lab\/resources\/antigen-tests-guidelines.html. Accessed 10 Oct 2021."},{"issue":"2","key":"8171_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1017\/ice.2020.343","volume":"42","author":"DK Henderson","year":"2021","unstructured":"Henderson DK, Weber DJ, Babcock H, et al. The perplexing problem of persistently PCR-positive personnel. Infect Control Hosp Epidemiol. 2021;42(2):203\u20134.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"8171_CR5","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2, the virus that causes COVID-19. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/testing-overview.html. Accessed 14 Feb 2021.","DOI":"10.46234\/ccdcw2020.085"},{"issue":"7","key":"8171_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1261\/rna.076232.120","volume":"26","author":"MN Esbin","year":"2020","unstructured":"Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA. 2020;26(7):771\u201383.","journal-title":"RNA"},{"key":"8171_CR7","unstructured":"COVID-19 Test Directory. https:\/\/www.finddx.org\/tools-and-resources\/dxconnect\/test-directories\/covid-19-test-directory. Accessed 17 Nov 2022."},{"key":"8171_CR8","unstructured":"Abbott. BinaxNOW COVID-19 Ag Card Home Test \u2013 Instructions for Use, version 3.4. https:\/\/www.fda.gov\/media\/144574\/download. Accessed 23 Aug 2021."},{"issue":"7","key":"8171_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/infdis\/jiaa802","volume":"223","author":"G Pilarowski","year":"2021","unstructured":"Pilarowski G, Lebel P, Sunshine S, et al. Performance characteristics of a rapid severe acute respiratory syndrome Coronavirus 2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021;223(7):1139\u201344.","journal-title":"J Infect Dis"},{"issue":"5","key":"8171_CR10","doi-asserted-by":"publisher","first-page":"e00083","DOI":"10.1128\/JCM.00083-21","volume":"59","author":"NR Pollock","year":"2021","unstructured":"Pollock NR, Jacobs JR, Tran K, et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. J Clin Microbiol. 2021;59(5):e00083-e121.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"8171_CR11","doi-asserted-by":"publisher","first-page":"e02880","DOI":"10.1128\/JCM.02880-20","volume":"59","author":"GA Perchetti","year":"2021","unstructured":"Perchetti GA, Huang ML, Mills MG, Jerome KR, Greninger AL. Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag Card. J Clin Microbiol. 2021;59(3):e02880-e2920.","journal-title":"J Clin Microbiol"},{"key":"8171_CR12","unstructured":"Abbott RealTime SARS-CoV-2 \u2013 Instructions for Use. https:\/\/www.fda.gov\/media\/136258\/download. Accessed 19 Nov 2022."},{"key":"8171_CR13","unstructured":"SARS-CoV-2 Assay (Panther Fusion System\u00ae) \u2013 Instructions for Use. https:\/\/www.fda.gov\/media\/136156\/download. Accessed 19 Nov 2022."},{"key":"8171_CR14","unstructured":"Centers for Disease Control and Prevention. Ending Isolation and Precautions for People with COVID-19: Interim Guidance. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/duration-isolation.html. Accessed 20 Feb 2022."},{"issue":"32","key":"8171_CR15","doi-asserted-by":"publisher","first-page":"2001483","DOI":"10.2807\/1560-7917.ES.2020.25.32.2001483","volume":"25","author":"A Singanayagam","year":"2020","unstructured":"Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25(32):2001483.","journal-title":"Euro Surveill"},{"issue":"3","key":"8171_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40121-020-00324-3","volume":"9","author":"SN Rao","year":"2020","unstructured":"Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9(3):573\u201386.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"8171_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10096-020-03913-9","volume":"39","author":"B La Scola","year":"2020","unstructured":"La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39(6):1059\u201361.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"8171_CR18","doi-asserted-by":"publisher","first-page":"e02589","DOI":"10.1128\/JCM.02589-20","volume":"59","author":"F Fenollar","year":"2021","unstructured":"Fenollar F, Bouam A, Ballouche M, et al. Evaluation of the Panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19. J Clin Microbiol. 2021;59(2):e02589-20.","journal-title":"J Clin Microbiol"},{"key":"8171_CR19","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1002\/jmv.27220","volume":"93","author":"S Carbonell-Sahuquillo","year":"2021","unstructured":"Carbonell-Sahuquillo S, L\u00e1zaro-Carre\u00f1o MI, Camacho J, et al. Evaluation of a rapid antigen detection test (Panbio\u2122 COVID-19 Ag Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a pediatric emergency department. J Med Virol. 2021;93:6803\u20137.","journal-title":"J Med Virol"},{"issue":"3","key":"8171_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmi.2020.11.004","volume":"27","author":"E Albert","year":"2021","unstructured":"Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio\u2122 COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27(3):472.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"8171_CR21","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.jcvp.2021.100011","volume":"1","author":"P Kuo","year":"2021","unstructured":"Kuo P, Realegeno S, Pride DT. Comparison of two nucleic acid amplification tests (NAATs) and two antigen tests for detection of SARS-COV-2 from upper repiratory specimens. J Clin Virol Plus. 2021;1(1):100011.","journal-title":"J Clin Virol Plus"},{"issue":"11","key":"8171_CR22","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/jmv.25952","volume":"92","author":"N Li","year":"2020","unstructured":"Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. J Med Virol. 2020;92(11):2286\u20137.","journal-title":"J Med Virol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08171-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:05:53Z","timestamp":1681819553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8171"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08171-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Cook County Health Institutional Review Board (Reference number: IORG0000119) deemed this study titled 20-165Q-Stroger as exempt due to it being a quality assurance project. Only the patients who provided informed consent to receive both the PCR and Binax-CoV2 tests were included in this validation study. The study adhered to the tenets of the Declaration of Helsinki and the regulations of the Health Insurance Portability and Accountability Act of 1996.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}